IP Library › Granted Patent US 8,017,730
Granted Patent B2
US 8,017,730 · App. 11/915,190 · Granted Sep 13, 2011

T cell receptors which specifically bind to VYGFVRACL-HLA-A24

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,017,730
App. No.
11/915,190
Granted
Sep 13, 2011
Kind
B2
Abstract

The present invention provides isolated T cell receptors (TCRs) having the property of specifically binding to the VYGFVRACL (SEQ ID NO:1)-HLA-A24 peptide-MHC. Such TCRs are useful, either alone or associated with a therapeutic agent, for targeting cancerous cells presenting the complex.

Claims (5)

1. An isolated T cell receptor (TCR) having the property of specifically binding to VYGFVRACL (SEQ ID NO:1)-HLA-A24 selected from the group consisting of TCRs which comprise:

SEQ ID NO: 2 and SEQ ID NO: 3;

SEQ ID NO:19 and SEQ ID NO:3;

SEQ ID NO:15 and SEQ ID NO:16; and

SEQ ID NO:20 and SEQ ID NO:16.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE PREVIOUSLY RECORDED AT REEL: 030824 FRAME: 0150. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 10, 2020
From: IMMUNOCORE LIMITED
To: IMMUNOCORE LIMITED; ADAPTIMMUNE LIMITED
Reel/Frame 054373/0041 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2013
From: IMMUNOCORE LIMITED
To: ADAPTIMMUNE LIMITED; IMMUNOCORE LIMITED
Reel/Frame 030824/0150 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2009
From: MEDIGENE LIMITED
To: IMMUNOCORE LIMITED
Reel/Frame 022076/0044 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2008
From: JAKOBSEN, BENT KARSTEN; LI, YI
To: MEDIGENE LIMITED
Reel/Frame 021079/0565 →